CURE Pharmaceutical Holding Corp

Detailed Description

CURE Pharmaceutical Holding Corp., together with its subsidiaries, operates as a technology focused vertically integrated drug delivery and product development company in the pharmaceutical, and health and wellness markets. It focuses on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms to enhance drug safety, efficacy, and patient adherence. The company operates through two business segments: Cure and Sera Labs. Its pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. The company also sells various wellness products under its distribution partners' brands. In addition, it is developing 50,000IU and Vitamin D3 OTF for oral administration. The company has a licensing agreement with Canopy Growth Corporation. CURE Pharmaceutical Holding Corp. was founded in 2011 and is based in Oxnard, California.